AdaptHealth/$AHCO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AdaptHealth

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.

Ticker

$AHCO
Sector
Primary listing

Employees

10,500

AdaptHealth Metrics

BasicAdvanced
$1.2B
16.81
$0.54
1.59
-

What the Analysts think about AdaptHealth

Analyst ratings (Buy, Hold, Sell) for AdaptHealth stock.

Bulls say / Bears say

AdaptHealth delivered a full‐year 2024 net income of $90.4 million compared to a $678.9 million loss in 2023, while adjusted EBITDA grew 2.7% to $688.7 million and free cash flow increased to $235.8 million, reflecting a strong financial turnaround (AdaptHealth).
In Q4 2024, the company beat expectations with adjusted EPS of $0.34 versus $0.28 consensus and revenue of $856.6 million topping estimates of $829.2 million, demonstrating effective execution in a challenging environment (Investing.com).
In Q1 2025, cash flow from operations rose to $95.5 million from $49.0 million a year earlier and free cash flow nearly breakeven at −$0.1 million versus −$38.9 million, underscoring significant improvement in working capital and liquidity management (AdaptHealth).
In Q1 2025, AdaptHealth’s net revenue fell 1.8% year-over-year to $777.9 million and adjusted EBITDA declined 19.3% to $127.9 million, highlighting operational headwinds early in the year (AdaptHealth).
During Q2 2025, net income dropped to $14.7 million from $19.4 million a year earlier and adjusted EBITDA contracted 5.9% to $155.5 million, underscoring ongoing margin pressure in core segments (AdaptHealth).
The company’s fiscal 2025 guidance for net revenue of $3.22 billion–$3.36 billion implies organic growth of −1% to +3%, signaling only modest top-line expansion amidst a competitive home medical equipment market (AdaptHealth).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.

AdaptHealth Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AdaptHealth Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AHCO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs